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Receptor traffickingThe α7 subtype of nicotinic acetylcholine receptors (AChRs) is one of the most abundant members of the Cys-
loop family of receptors present in the central nervous system. It participates in various physiological pro-
cesses and has received much attention as a potential therapeutic target for a variety of pathologies. The im-
portance of understanding the mechanisms controlling AChR assembly and cell-surface delivery lies in the
fact that these two processes are key to determining the functional pool of receptors actively engaged in syn-
aptic transmission. Here we review recent studies showing that RIC-3, a protein originally identified in the
worm Caenorhabditis elegans, modulates the expression of α7 AChRs in a subtype-specific manner. Potentia-
tion of AChR expression by post-transcriptional events is also critically assessed.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
AChRs are members of the Cys-loop family within the ligand-gated
ion channel (LGIC) superfamily and are assembled from a diverse col-
lection of subunits forming pentameric transmembrane receptors hav-
ing different properties and functions (for reviews see [1–10]). All
subunits comprise a large N-terminal extracellular domain, four α-
helical transmembrane segments and a small C-terminal extracellular
domain. In vertebrate species, 17 subunits (α1–α10, β1–β4, γ, δ and
ε) have been identified to date, α1, β1, γ, δ and ε being expressed at
the neuromuscular junction and the electromotor synapse and the
remaining subunits (α2–α10 and β1–β4) at the central and peripheral
nervous system (reviewed in [1,6,11–15]).
The homomeric α7 AChR is one of the most abundant AChR sub-
types in the mammalian central nervous system [15–17]. The highest
levels of expression of this subtype of receptor are found in the hippo-
campus, an area of the brain involved in various aspects of learning
andmemory [18–22].α7 AChRs can act at the presynaptic, postsynaptic
or perisynaptic levels to facilitate the liberation of neurotransmitters,
mediate synaptic transmission, ormodulate the connections of different
neurons by activating diverse second messenger routes [1,19,23–31].
The α7 AChR transcripts are also found in non-neural, peripheral tis-
sues, ranging from vascular endothelium to skin, T-cells, macrophages,
or lung epithelial cells, and high levels of expression of α7 transcripts
are present in mammalian sperm cells, implicating a role for α7 AChR
in the reproductive system [32–46].lar Neurobiology, PIB UCA-
07AFF Buenos Aires, Argentina.
l rights reserved.AChRs have been linked to many neurodegenerative disorders
[13,47–60]. A complete characterization of AChR synthesis, assembly
and trafficking constitutes a fundamental step in understanding the
physiological mechanisms that may contribute to the development
of drugs for treating these diseases. In this reviewwe describe the com-
plex processes and actors enabling proper mature AChR formation as
well as the several steps required for AChRs to reach the plasma mem-
brane and become functional ion channels.
2. Synthesis, folding and assembly of α7 AChRs
The efficacy of synaptic transmission depends largely on the pop-
ulation of active AChRs at the synapse. However, the assembly of ion
channels such as the AChR is a slow and inefficient process, with only
30% of newly synthesized subunits forming functional receptors upon
adopting the correct transmembrane topology and undergoing critical
post-translational modifications [8,61–65]. Biosynthesis of α7 AChR in
various mammalian cells has been reported, but functional heterolo-
gous expression has been very hard to attain [66–70].
Most AChR subunits appear to be incapable of forming functional
AChRs unless they co-assemble with at least one other type of subunit
in a heteromeric complex. However, the neuronal α7 and the α8 sub-
units are the only ones which appear to preferentially form homomeric,
rather than heteromeric, receptors in heterologous expression systems
[71–74].
Each subunit of the AChR is a separate gene product with a pro-
cessed signal sequence and one to three N-linked glycosylation sites
[75,76]. As they are synthesized, the subunits are inserted into the
lumen of endoplasmic reticulum (ER) membranes which contain the
proteins required for efficient protein folding and post-translational
modification [63,77,78]. The latter is well documented for the AChR,
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[79–81], palmitoylation [82,83], proline isomerization [63] and proteo-
lytic cleavage of the N-terminus signal sequence in the ER [63].
Previous studies performed on the α7 AChR suggest that inappro-
priate disulphide-bond formation precludes correct subunit folding,
as observed in some mammalian cell lines [84]. Additionally, the pro-
lyl isomerase enzyme cyclophilin has been shown to be necessary for
efficient folding of the α7 subunit in Xenopus oocytes [85–88].
Recent studies [89,90] have highlighted the importance of the
α-helix present at the N-terminus of the α7 AChR subunits as well as
the interaction of the α-helix with loop 3 between β-strands β2 and β3
in the expression of functional channels. Evidence shows that the latter
interaction is relevant during receptor biogenesis, most likely by favoring
or initiating the correct global folding required for receptor assembly.
After subunit synthesis, properly folded and oligomerized AChRs
are transported from the ER along the exocytic pathway [1,61,91].
3. The role of chaperone proteins
There is evidence that AChR folding, assembly and trafficking are
influenced by several chaperone proteins, such as the 14-3-3 protein
[92,93], BiP [94–96] or calnexin [97–99]. Rapsyn is essential for AChR
clustering in muscle [100] and has also been detected in non-muscle
cells, including neurons of the ciliary ganglia [101,102], fibroblasts
[103], myocardial cells, and Leydig cells [104].
Rapsyn hasmore recently joined the above chaperone club, as it “es-
corts” the AChR from the ER to the plasmalemmawhen heterologously
expressed in mammalian cells [105]. All these proteins have been
shown not only to influence the trafficking of the AChR subunits but
also to interactwith a diverse range of target proteins [93,106]. More re-
cently, the transmembrane protein resistant to inhibitors of cholines-
terase (RIC-3), originally identified in Caenorhabditis elegans, has been
classed as a much more selective chaperone of the AChR [71,107–112].
Regulation of receptor subunits by the proteasome, the large pro-
tein complex that proteolytically degrades unneeded proteins, has
also been demonstrated [113,114]. Furthermore, the proteasome in-
directly regulates synaptic transmission mediated by AChRs via regu-
lation of RIC-3 [113].
3.1. RIC-3 is a selective AChR chaperone
The RIC-3 protein was first identified in 1995 in the nematode C.
elegans as a protein encoded by the gene ric-3 [71,77,110,115,116].
In C. elegans, RIC-3 is necessary for synaptic transmission mediated
by neuronal AChRs but not by other LGICs [71,77,109]. RIC-3 is a highly
charged protein containing no less than 8% aspartic acid, 13% glutamic
acid, 10% lysine and 8% arginine [77,110,112,115] residues. It comprises
an N-terminal domain, a membrane-spanning domain separated by a
proline-rich spacer, and a cytosolic C-terminal domain having two
coiled-coil domains. The position of the former is still unclear as in
some vertebrates the first transmembrane domain may function as a
signal peptide (Fig. 1) [77,78,110,112,115,117–120].
Homologs of the gene ric-3 have been identified in a great number
of species such as the invertebrates Ostertagia ostertagi and Drosophila
melanogaster, and the vertebrates Xenopus laevis, Danio rerio, Mus
musculus, and Homo sapiens [109]. The H. sapiens ric-3 homolog
shares 22% of the sequence with the C. elegans ric-3 gene and its struc-
ture differs merely in having a shorter N-terminal domain and only one
coiled-coil domain (Fig. 1) [71,109,112,115,121]. Five distinct tran-
scripts of human ric-3 (a, b, c, d and e) have been found
[109,117,119]. The ric-3a isoform is encoded by clones AY326435
and BC022455 (GenBank® nucleotide sequence database accession
numbers). These human ric-3 homologs are 2.9 kb in length. The
BC022455 clone shares sequence identity with AY326435 except
for a single serine. Transcript AK021670 is 1.5 kb long and corresponds
to isoform ric-3b, which encodes only for a soluble coiled-coil domain[109]. Transcript AL832601 is 5.2 kb in length and corresponds to iso-
form ric-3c. The latter isoform encodes for the first membrane-
spanning domain spliced directly to the C-terminus. The isoform ric-3d,
corresponding to clones AY326436/AY358475 and BI832705, codes for
the two trans-membrane domains only [118]. Finally, ric-3e (GenBank®
nucleotide sequence database accession number AM422214) encodes a
RIC-3 protein of 288 amino acids which lacks the coiled-coil domain
and part of the C-terminal sequence [119].
3.2. Regulation of AChR by RIC-3
The degree of AChR regulation depends on various factors such as
receptor and cell type (see Table 1) [67,71,111]. The neuronal receptor
DEG-3/DES-2 is one of the four well-characterized AChRs in C. elegans
[121]. Co-expression with RIC-3 was shown to be required for AChR ac-
tivity in C. elegans body muscles and for enhanced AChR activity in
Xenopus oocytes [110,112]. Co-immunoprecipitation studies have also
provided proof of an interaction between RIC-3 and the α7 AChR subu-
nit [71,111] and the α3, α4, β2 and β4 AChR subunits [71]. In contrast,
RIC-3 caused a marked inhibition of functional responses with hetero-
meric α3β4 and α4β2 AChRs in Xenopus oocytes [109]. Co-expression
of RIC-3 and chick α8 subunits in heterologous cell lines enhances
AChR functional expression [71]. Co-expression of RIC-3 apparently
has no effect on α9 or α10 AChR expression in cultured mammalian
cell lines [71] and functional expression of α9α10 AChR in cultured
mammalian cells is rare [71,122–124] Nevertheless, recent studies sug-
gest that although co-expression of RIC-3 has no effect on the binding
of 125I-α-bungarotoxin to either homomeric α9 or α9α10 heteromeric
receptors [122], such co-expression might enhance the effect of rapsyn
on AChR clustering at the cell surface. Osman et al. [122] find that RIC-3
expression increases the total amount ofα9AChR in CL4 cells, supporting
the view that RIC-3 regulates AChR trafficking by increasing the number
of mature or correctly folded receptor subunits reaching the cell surface.
Alternatively, RIC-3 might affect α9 levels in CL4 cells by regulating the
turnover of theα9 receptor subunits.With the exception of the 5-HT3 re-
ceptor, RIC-3 appears to have little or no effect upon other LGICs, includ-
ing those activated by GABA and glutamate [71,85,109,112,118].
Additional host cell factors appear to be involved in modulating the
chaperone activity of RIC-3 on AChRs [71,85,108–111,118,119,125]. Co-
expression of RIC-3 with the 5-HT3 receptor in X. laevis oocytes totally
abolishes 5-HT3 surface expression [108,109]. In contrast, RIC-3 was
reported to enhance functional expression of 5-HT3 receptors in a
human kidney cell line [85,118,126]. It is noteworthy that RIC-3 has
been shown to increase α7 AChR heterologous expression both in X.
laevis oocytes and in HEK-293, CHO and SHE-P1 mammalian cell lines
[66,71,77,107–112,119,125]. The evidence therefore suggests that RIC-
3 is required for the correct folding of the α7 AChR and for it to attain
functional expression in all cell systems tested so far.
Since all published results concur that RIC-3 interacts with α7 AChR,
it is likely thatα7AChR distribution correlateswith that of theRIC-3 pro-
tein. In general this is the case, although α7 AChR labeling is low [117].
Purkinje cells in the cerebellumappear to be an exception; these cells ex-
pressα7 protein but, as previously stated, exhibit no detectable levels of
RIC-3 [117]. There are also discrepancies in the functionality of the α7
AChRs expressed in these cells [127]. Such discrepancies may apply as
well to cell lines that lack RIC-3 expression and upon transfection with
α7 cDNA are incapable of expressing functional α7 AChRs at their cell
membrane [111]. Interestingly, RIC-3 is also detected in some areas of
the brain (corpus callosum, pituitary gland and the cerebellum) which
express relatively low levels ofα7 AChR (see below), suggesting that al-
ternative mechanisms are operative in these loci to catalyze maturation
of α7 AChR [119].
Ric-3 transcripts and RIC-3 protein are not confined to brain areas.
In C. elegans, RIC-3 is also required for maturation of the levamisole-
sensitive vulval muscle AChR and for maturation of the EAT-2 AChR
that enables pharyngeal pumping [112,113].
Fig. 1. The RIC-3 protein. In C. elegans, the RIC-3 protein (left) comprises an N-terminal domain (the exact position of which has not yet been clearly established), a membrane-
spanning domain separated by a proline-rich spacer, and a C-terminal domain exposed to the cytoplasmic compartment, which possesses two coiled-coil domains. The suggested
topology of the H. sapiens Ric-3 homolog (right) differs structurally simply in having a shorter N-terminal domain and only one coiled-coil domain [78].
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Analysis of the distribution of ric-3 transcripts and RIC-3 protein
facilitates identification of their in vivo targets. The presence of ric-3
transcripts has been demonstrated in most regions of mouse brain
[109,111]. The areas with the highest ric-3 transcript signal were
the CA1–CA3 region of the hippocampus, the deep nuclei and the Pur-
kinje cell layer in the cerebellum, and the superior colliculus. In a
more recent study [117] focusing on the distribution of the RIC-3 pro-
tein in rat brain, the authors found that it was broadly distributed
with a moderate labeling intensity, in parallel with the localization
of the corresponding mRNA in mouse brain [109]. Different levels of
labeling were described: no signal was detected in the Purkinje cell
layer and the molecular layer of the cerebellum; weak labeling was
found in the granular layer and in pyramidal cells from different cor-
tical areas; and moderate labeling was observed in the dentate gyrus
and the CA1 and CA3 neurons of the hippocampus. Except for the me-
dial habenula, where neurons were intensely labeled, all neuronsTable 1
Regulation of the level of expression of the nicotinic receptor by RIC-3 depends on the
LGIC and cell type.
Receptor Cell type Effect Reference
DEG-3/DES-2 C. elegans Enhanced expression [109,112,121]
DEG-3/DES-2 X. laevis oocytes Enhanced expression [109,112,121]
α7 AchR X. laevis oocytes Enhanced expression [108,112,202]
α7 AChR Mammalian cells Enhanced expression [66,71,108,111,125,202]
α8 AchR Mammalian cells Enhanced expression [71]
α9 AChR Mammalian cells Unaffected [71]
α9 AChR Mammalian cells Enhanced expression [122]
α9α10 AChR Mammalian cells Unaffected [71]
α3β4 AChR Mammalian cells Enhanced expression [71]
α4β2 AChR X. laevis oocytes Inhibited expression [107,109]
α3β2 AChR Mammalian cells Enhanced expression [71]
α4β2 AChR Mammalian cells Enhanced expression [71]
α4β4 AChR Mammalian cells Enhanced expression [71]
5-HT3A Mammalian cells Enhanced expression [85,118,126]
α7/5-HT3A Mammalian cells Inhibited expression [108]
α7/5-HT3A X. laevis oocytes Inhibited expression [108]
GABA X. laevis oocytes Unaffected [77,109,112]
GABA Mammalian cells Unaffected [71,85]
Glutamate X. laevis oocytes Unaffected [71,77,109,112]
Glycine X. laevis oocytes Unaffected [71,109,112]from the thalamus as well as the striatum, the globus pallidum, the
hypothalamus (primarily in the mammillary nuclei) and the substantia
nigra neurons also displayed labeling ofmoderate intensity. The highest
intensities of immunoreactivity to RIC-3were found in the inferior olive
and also in the dorsal cochlear nucleus, in the solitary complex, and in
motor nuclei, such as trigeminal (V), abducens (VI), facial (VII) and hy-
poglossal (XII) nuclei in the brainstem. Interestingly neurons in the
deep cerebellar nuclei appeared intensely labeled. No ric-3 transcripts
were found in the dentate gyrus, although RIC-3 protein was detected.
The opposite was found in the Purkinje cell layer, where ric-3 tran-
scripts were found and no labeling for RIC-3 was observed. This lack
of correspondence between the distribution of ric-3 transcripts and
RIC-3 protein could be due to low levels of either protein or RNA,
which would prevent their detection. Ric-3 transcripts were detected
in some neuronal cell lines such as human neuroblastoma SH-SY5Y
and pheochromocytoma PC12 [111,117] cells; RIC-3 protein was
found in these cells. RIC-3 levels have been shown to increase during
differentiation of SH-SY5Y and PC12 cells. Themechanism that activates
RIC-3 expression upon cell differentiation has still not been clarified.
3.4. The endoplasmic reticulum is the arena for the chaperone action of RIC-3
Several studies support the view that RIC-3 is localized in the ER
[91,126]. Since RIC-3 has been shown to interact with mutant AChR
subunits that are unable to exit this organelle, it is highly plausible
that the interaction between RIC-3 and AChR subunits occurs in the
ER [85,91,108,111,112,118]. It is also possible that the missing chaper-
one in the work by Drisdel and coworkers [83] is no other than Ric-3.
If this is the case, the chaperone role of RIC-3 might consist in making
cysteine residues in α7 AChR accessible to palmitoylation at the ER, a
necessary step for subsequent functional expression at the plasma
membrane [82,83].This idea is in agreement with the fact that interac-
tion with RIC-3 stabilizes receptors or receptor assembly intermediates
[85,107].
It has been reported that both the N- and the C-terminal regions of
RIC-3 are needed for enhancing AChR expression [108]. The C-terminus
of all RIC-3 homologs contains one or two coiled-coil domains
[77,109,110,115,119,120], known to be important for protein–protein
interactions involved in the organization ofmolecular scaffolds, in addi-
tion to other functions [128]. However, deletion analysis of RIC-3 sug-
gests that ablation of the coiled-coil domain does not modify the
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[108,110]. Furthermore, the ric-3e isoform that contains deletions of the
coiled-coil domain and part of the C-terminal domain, mimics the capac-
ity of thewhole RIC-3 protein tomodulateα7 AChR subunits, promoting
α7 AChR surface expression and functional receptor activity [119]. Sim-
ilarly, no changes were found in the chaperone activity of naturally oc-
curring RIC-3 variants lacking the coiled-coil domain in D. melanogaster
[110]. It has been suggested that two other regions of RIC-3 are also
involved in protein–protein interactions in C. elegans, the first involving
the proline residues within the spacer between the two transmembrane
domains. These amino acidsmayprovide a structural scaffold onwhich to
anchor interacting proteins. The second region involves the membrane-
spanning domains. It is interesting that the second transmembrane do-
main in RIC-3 homologs shows conservation beyond that required for
traversing themembrane [109]. Transmembrane interactionsmay there-
fore bring together AChR subunits and the RIC-3 homologs, the effects of
RIC-3 thus being the result ofmore than one interactionmediated by sev-
eral domains within the RIC-3 molecule.
Aside from interacting with AChR subunits or 5-HT3 receptors,
RIC-3may be necessary for additional interactionswith yet unidentified
proteins to form a multiprotein maturation complex. Such machinery
may be required as a scaffold for the maturation of α7 AChRs.Fig. 2. Importance of a tight regulation of RIC-3 levels. BATH-42 interacts with the RIC-3 C-term
uration of α7 AChRs at the ER [113]. A) RIC-3 interacts with α7 subunits and enhances α7 AC
BATH-42 targets excess RIC-3 for degradation by the ubiquitin proteasome system, thus mainta
expression of BATH-42 is detrimental to AChR function, precluding RIC-3/AChR interaction. D) O
excess RIC-3may lead to formation of RIC-3 aggregates that sequester AChR subunits away fromFurthermore, proteins that interact with the RIC-3 C-terminus, such as
BATH-42, a BTB- (broad-complex, Tramtrack and bric-a-brac) and
MATH- (meprin-associated Traf homology), domain-containing pro-
tein, have recently been described [113]. Reduced expression of the lat-
ter protein has been shown to be detrimental to AChR function in C.
elegans [113] (See Fig. 2).
4. Mechanism of α7 AChR modulation by
phosphorylation/dephosphorylation
Protein phosphorylation and dephosphorylation are key mecha-
nisms for regulating the activity of membrane proteins such as ion
channels. For example, phosphorylation of glutamate receptors by
Src-family kinases (SFKs) is associated with long-term potentiation
(LTP) and spatial learning in the hippocampus [129–131]. Although
themechanisms that regulate phosphorylation of AChRs are still essen-
tially unknown, protein tyrosine phosphorylation by the SFKs has been
shown to affect peripheral AChRs in variousways, depending on the tis-
sue, subunit type and functional role of the receptors involved. Inmam-
malian muscle, SFKs interact with the AChR [132] and play a major role
in receptor clustering and cytoskeletal anchoring of AChRs at the neuro-
muscular junction [133–140].inus and may form amultiprotein maturation complex required as a scaffold for themat-
hR assembly at the ER. B) Under physiological conditions RIC-3 is regulated by BATH-42.
ining optimal levels of the chaperone and facilitating properα7 AChR formation. C) Over-
verexpression of RIC-3 influences AChR distribution and function. Data suggest [113] that
the assembly process, thereby leading to a reduction in the formation of functional AChRs.
Fig. 2 (continued).
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subtle changes in desensitization kinetics but not in Imax, the maximal
current flowing through the receptor channel [141–143]. In adrenal
medulla chromaffin cells the tyrosine kinases c-SRC and FYN associate
with the α3β4 receptor and are involved in the cholinergic stimulation
of catecholamine secretion [141,144,145].
In cortical neurons, FYN associates with the α7 AChR [146,147].
Recent studies have also demonstrated the importance of the phos-
phatidylinositol 3-kinase (PI3K) pathway downstream of AChRs in pro-
tecting neurons from death and up-regulating these receptors [148].
Specifically, it has been shown that upon stimulation,α7AChR activates
PI3K via direct association with non-receptor type tyrosine kinase FYN
and Janus-activated kinase 2 (JAK2), promoting the survival of neuronal
cells (Fig. 3). This in turn proceeds via activation of the Akt-Bcl-2 path-
way [149] since treatmentwith PP2, AG490, LY294002 andwortmannin-
inhibitors of Fyn, JAK2 and PI3K, respectively- significantly inhibitsneuroprotection by donepezil and galantamine, two acetylcholinester-
ase inhibitors [146].
A recent study [141] demonstrated that the balance between phos-
phorylation and de-phosphorylation of the α7 AChR by SFKs did in-
deed modify the Imax but not the time-course of the response in
oocytes, SH-SY5Y cells, and hippocampal interneurons. The α7 subu-
nit present inmammalian spermatozoa also associateswith amember
of the SFKs [32]. Tyrosine phosphorylation of α7 AChR was found to
negatively regulate receptor activity in neuroblastoma cells, hippo-
campal CA1 interneurons, and supraoptic magnocellular neurons,
whereas de-phosphorylation of α7 AChR was found to potentiate
ACh-evoked currents in these cells. The mechanism of α7 modulation
by phosphorylation does not involve modification of the number and
clustering of receptors at the cell surface [141]. Instead, the potentia-
tion induced by de-phosphorylation of α7 AChRs must stem from
mechanisms other than insertion of additional receptors into the cell
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SFKs affects the number of activatable receptors at the plasma mem-
brane, such that de-phosphorylated receptors are responsive, whereas
phosphorylated receptors are probably nonresponsive to agonist. Collec-
tively, these observations suggest that modulation of the α7 AChR by
SFKs constitutes an important regulatory mechanism for the activity of
receptors at the cell surface.5. Mechanism of α7 AChR modulation by brain-derived neuro-
trophic factor (BDNF)
BDNF regulates development of neuronal structures both in the pe-
ripheral and central nervous systems [150–155]. It has acute effects on
the synapse, serving as an activity-dependent regulator of synaptic plas-
ticity and participating in rapid synaptic transmission [150,151,156–159],
in thematuration of GABAergic signaling and in the stabilization of newly
formed synapses [151,160–163]. BDNF can also influence the level of α7Fig. 3. α7 AChRs activate downstream signaling pathways. Co-immunoprecipitation
studies have demonstrated that phosphatidylinositol 3-kinase (PI3K) and non-
receptor type tyrosine kinase (Fyn) are physically associated with α7 AChR [147].
When stimulated,α7 AChRs activate PI3K and promote survival of neuronal cells via acti-
vation of Akt-Bcl-2 pathway [147]. Other studies demonstrate that janus-activated kinase
2 (JAK2) stimulates survival via the latter antiapoptotic pathway [146].AChRs subunits (Fig. 4) in the hippocampus and other brain regions
[160,164,165]. Recent studies using dissociated rat hippocampal neurons
in culture demonstrated that BDNF increases both surface and internal
α7 AChRs pools. This increment depends on glutamatergic activity and
is restricted to distinct neuronal subtypes, suggesting the existence of
cell-type specific regulatorymechanisms. In particular, interneurons inhi-
biting glutamatergic cells show large increments in α7 AChRs when ex-
posed to BDNF, possibly due to de novo synthesis, since long exposure
to BDNF is required to detect the increases in α7 AChRs [160].
6. α7 AChR trafficking depends on soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs)
Recently, α7 AChRs were found to co-distribute postsynaptically
with target soluble SNAREs [166] (Fig. 5). Furthermore, nicotinic
stimulation rapidly induced SNARE-dependent vesicular endocytosis
accompanied by receptor internalization [166]. However, the number
of surface α7 AChRs was not modified since a SNARE-dependent pro-
cess also recruited receptors to the cell surface from internal pools
(Fig. 5). It is interesting to note that trafficking of α7 AChRs induced
by nicotine and dependent on SNARE proteins, both for receptor in-
ternalization and receptor recruitment to the cell surface, is a rapid
process. This differs significantly from previously described forms of
trafficking for other nicotinic receptors, which operate on slower
time scales [167,168]. Furthermore, at the neuromuscular junction
and for muscle AChRs expressed in CHO-K1/A5 cells, receptor blockade
has been shown to accelerate the rate of nicotinic receptor removal but
both the mechanism and time course differ significantly from those
seen forα7 AChRs [169,170]. Additionally, SNARE-dependent trafficking
was required for α7 AChRs to be capable of activating the transcription
factor cAMP response element-binding protein and attendant gene ex-
pressionwhen challenged. In other words, SNARE-dependent trafficking
appears to be necessary for maintaining a functional link between α7
AChR responses and downstream signaling on somatic spines.
7. α7 AChR trafficking is influenced by the M3–M4 cytoplasmic loop
AChR subunits share a common topology, having a large N-terminal
extracellular domain containing the ligand-recognition sites, four trans-
membrane domains (M1–M4), a large cytoplasmic domain between
M3 andM4, which is highly divergent among different subtypes, and fi-
nally an extracellular C-terminal domain. Alignment of the first twenty
amino acids of theM3–M4 cytoplasmic domain reveals a stretch of nine
amino acids present in all AChR subunits that consists of two pairs of hy-
drophobic amino acids separated by five non-conserved amino acids.
The cytoplasmic domain has been shown to be critical for the assembly
of functionalα7AChRs [171] and for trafficking ofα4β2AChRs from the
ER to the cell surface [172]. Mutations in this region ofα7 subunitswere
found to abolish expression of mature AChRs, apparently by inhibiting
conformational maturation of the subunits and consequently prevent-
ing their assembly into mature AChRs in the ER. A recent study showed
thatmutation of amino acids from this region (leucines 335, 336 or 343)
to alanine reduced cell-surface expression of α7 AChRs [173]. Similar
mutations in α4 and β2 subunits did not prevent assembly of mature
α4β2 AChRs, whichwere capable of binding cholinergic ligands though
unable to reach the cell surface [172]. These results suggest that muta-
tions in the M3–M4 cytoplasmic domain affect α7 AChR biogenesis
but not that of the α4 and β2 subunits.
The M3–M4 cytoplasmic domain of the AChR subunits has also
been found to regulate targeting of neuronal AChRs (to pre- or post-
synaptic sites). The influence of this region upon receptor targeting
has been previously studied using expression of subunit chimeras in
chick ciliary ganglion neurons by retrovirus-mediated gene transfer
[174]. Mutational analysis performed in these neurons by changing
the M3–M4 cytoplasmic loop of the α7 subunit for the analogous
loop region of the α3 subunit resulted in alterations of α7 subunit
Fig. 4. α7 AChRs aremodulated by brain-derived neurotrophic factor (BDNF). BDNF can in-
fluence the level of α7 AChR subunits in the hippocampus and other systems [164,165] by
increasing both surface and internal pools of α7 AChRs, possibly by de novo synthesis of
α7 AChRs. This increment depends on glutamatergic activity and is cell-type specific.
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M3–M4 cytoplasmic loop was replaced by that of either α5 or α4 sub-
units, no such effect was observed, implying that amino acid sequences
within the M3–M4 cytoplasmic loop of the α3 subunit are involved in
the targeting of receptors to postsynaptic regions in ciliary ganglion
neurons [1,174,175]. Additionally, sequence motifs responsible for dif-
ferential targeting to axons and dendrites have also been identified
within these regions of the α4 and α7 subunits [176]. All in all, these
studies highlight the importance of the M3–M4 domain and its influ-
ence on subunit folding, cell-surface expression and receptor targeting
[177].
8. Pathological α7 AChR synthesis, assembly and exocytic trafficking
Theubiquitous occurrence andparticipation of theα7AChRs inmany
cellular and physiological processes is bound to have pathological coun-
terparts. The α7 AChR subtype has received much attention as a poten-
tial therapeutic target for a variety of pathologies [50,51,146,178–187].
Reduction of α7 AChRs in the CNS is linked with Alzheimer dis-
ease, which has been shown to lead to neuronal loss [53,188–190].One of the salient events at early stages of this disease (usually pre-
clinical) is the impairment in hippocampus-based episodic memory
which can be improved by enhancement of cholinergic transmission
[191]. Another important event that associates well with the Alzheimer
disease pathology is the aggregation of the β-amyloid peptide [53]. This
peptide interacts withα7 AChRs and has been reported to affect the nor-
mal functioning of the latter, causing reduced neuronal survival
[146,192–194].
Decreased expression of α7 AChR has also been associated with
schizophrenia [51,195–197]. Since α7 AChRs are highly permeable
to calcium [198] and increased calcium permeability is required for
neuronal migration [199], neurons with less α7 AChRs would fail to
migrate to their correct destinations [200] and be activated by
acetylcholine.
The role of RIC-3 in disease-associated cholinergic dysfunction is
currently undefined. Interestingly, levels of RIC-3 mRNA are elevat-
ed in postmortem brains of individuals with bipolar disorder and
schizophrenia [181], and a link has been suggested between defi-
cient RIC-3 mediated chaperoning of an AChR subunit and individ-
uals with bipolar disorder and psychotic symptoms [181]. Excess
RIC-3 has been reported to be deleterious for AChR function and dis-
tribution, giving rise to the need for chaperone regulation [113,126].
Under physiological conditions, BATH-42 activity maintains optimal
levels of RIC-3 by targeting excess RIC-3 for degradation by the protea-
some (Fig. 2B). Consequently, inhibition of the proteasome leads to in-
creased amounts of AChRs. Loss of function of BATH-42 interferes with
AChR function by causing RIC-3 to increase [113]. In turn, overexpres-
sion of RIC-3 leads to formation of RIC-3 aggregates, reducing the
amount of AChR subunits available for the formation of functional re-
ceptors [113] (Fig. 2D). Interestingly, overexpression of BATH-42 leads
to a reduction of α7AChRs since it sends RIC-3 for degradation by the
proteasome (Fig. 2C) and inhibition of the proteasome consequently
leads to increased amounts of AChR. This suggests that a balance be-
tween degradation and assembly regulates the level of mature AChRs
[113,114].
The α7 AChR expressed in macrophages plays an important role in
the cholinergic anti-inflammatory pathway [45,180]. During acute in-
flammatory processesα7AChRs attenuate renal failure induced by ische-
mia/reperfusion by inhibiting pro-inflammatory cytokine expression,
and subsequently decreasing cell apoptosis [180,201]. Therefore a strict
regulation of the levels of expression of α7 AChRs appears to be of key
importance to the correct maintenance of physiological mechanisms
within a wide spectrum of cells and tissues in the organism.9. Concluding remarks
The neuronal-type α7 AChR interacts with different proteins at
different stages of its biosynthesis, folding, assembly, and trafficking.
The participation of the chaperone protein RIC-3 is of unique importance
in the life of theα7 AChR, constituting an essential requirement for func-
tional expression. Functional potentiation is also mediated by post-
transcriptional events such as SFKphosphorylation or phosphatase activ-
ity. Additionally, SNARE protein-dependent trafficking appears to be
necessary for maintaining a functional link between α7 AChR responses
and downstream signaling, at least in neuronal somatic spines. Structural
analysis of theα7 AChR proteins has shown that trafficking is also influ-
enced by the M3-M4 cytoplasmic loop whereas receptor assembly re-
quires the interaction between the N-terminal α-helix and the
β-strands β2 and β3.
AChRs have been linked to many neurodegenerative diseases and
numerous studies for palliative treatments are currently underway. A
complete characterization of AChR synthesis, assembly and trafficking
constitutes a fundamental step in understanding physiological mecha-
nisms which may contribute to the development of therapeutic drugs
for treating these diseases.
Fig. 5. α7 AChRs are modulated by soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE). α7 AChRs on neurons are subject to rapid SNARE dependent
trafficking [166]. The latter is bidirectional, involving both internalization of activated α7 AChRs and recruitment of new receptors from intracellular pools to repopulate the plasma
membrane. This process is dependent on extracellular calcium and may thus be initiated by α7 AChR activation, since the α7 AChR is extremely permeable to Ca2+.
725A.S. Vallés, F.J. Barrantes / Biochimica et Biophysica Acta 1818 (2012) 718–729Further studies are required to fully elucidate the exactmechanisms
that determine receptor maturation. Among the issues remaining to be
addressed are whether different subunit domains influence assembly
and trafficking; what determines the functional state of AChRs; what
determines subtype specificity of chaperone proteins; and the role of
scaffolding proteins in AChR targeting to the plasma membrane. These
and more are just some of the pieces of a still unresolved puzzle.Acknowledgements
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